Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
Japanese biotech J-Pharma said on January 23 that its L-type amino acid transporter 1 (LAT1) inhibitor nanvuranlat (JPH203) achieved the primary goal in a PII study conducted in Japan for the treatment of refractory, advanced biliary tract cancers. The primary…
To read the full story
Related Article
- Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
April 26, 2019
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
BUSINESS
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
- Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
February 2, 2026
- Astellas, MSD Seek Japan Nod for Padcev/Keytruda in Perioperative MIBC
February 2, 2026
- Alfresa Launches End-to-End Platform to Support Biotech Entry into Japan
February 2, 2026
- Nichi-Iko’s Xarelto Generic Adds VTE Use
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…